DXCM vs SYK: fair value comparison
DexCom, Inc. and Stryker Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DXCM currently sits closer to the top of our discount ranking. DXCM carries the stronger momentum grade.
| DXCM | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $90.82 | $330.69 |
| 12-month range | $58.22–$87.31 | $294.73–$389.94 |
| Sector rank | #21 of 113 Healthcare | #24 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | A | C |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: DXCM fair value analysis · SYK fair value analysis